A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO)
Uncontrolled Hypertension

About this trial
This is an interventional treatment trial for Uncontrolled Hypertension
Eligibility Criteria
Inclusion Criteria:
- Is on a stable regimen of background antihypertensive agent(s) for at least 8 weeks and would be considered a candidate for an additional antihypertensive agent at the time of screening ;
- Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHG;
- Demonstrates they are able to be adherent to the study drug and their anti-hypertensive medication during a run-in period
- If taking SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and
- Agrees to comply with the contraception and reproduction restrictions of the study;
Exclusion Criteria:
- Has a mean seated systolic blood pressure (SBP) ≥180 mmHG;
- Has a body mass index (BMI) >50 kg/m2;
- Is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache);
- Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part of an existing antihypertensive regimen;
- Has documented estimated eGFR <30 mL/min/1.73m2;
- Has known and documented New York Heart Association stage III or IV chronic heart failure;
- Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening;
- Major cardiac surgery within 6 months before Screening;
- Has chronic permanent atrial fibrillation;
- Has uncontrolled diabetes with glycosylated hemoglobin >10% at Screening;
- Has planned dialysis or kidney transplantation planned during the course of the study;
- Prior solid organ transplant and/or cell transplants;
- Sodium <130 mEq/L;
- Potassium <3.5 mEq/L;
- Potassium >5 mEq/L;
- White blood cell count >15 × E9/L or absolute neutrophil count <1 × E9/L at Screening;
- Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;
- Has typical consumption of ≥14 alcoholic drinks weekly;
Sites / Locations
- CinCor Site 27
- CinCor Site 35
- CinCor Site 69
- CinCor Site 6
- CinCor Site 20
- CinCor Site 70
- CinCor Site 36
- CinCor Site 29
- CinCor Site 46
- CinCor Site 47
- CinCor Site 49
- CinCor Site 52
- CinCor Site 57
- CinCor Site 31
- CinCor Site 18
- CinCor Site 41
- CinCor Site 28
- CinCor Site 9
- CinCor Site 1
- CinCor Site 12
- CinCor Site 54
- CinCor Site 13
- CinCor Site 17
- CinCor Site 16
- CinCor Site 34
- CinCor Site 14
- CinCor Site 33
- CinCor Site 40
- CinCor Site 42
- CinCor Site 50
- CinCor Site 72
- CinCor Site 63
- CinCor Site 7
- CinCor Site 21
- CinCor Site 30
- CinCor Site 59
- CinCor Site 19
- CinCor Site 25
- CinCor Site 38
- CinCor Site 38
- CinCor Site 22
- CinCor Site 64
- CinCor Site 11
- CinCor Site 65
- CinCor Site 15
- CinCor Site 24
- CinCor Site 4
- CinCor Site 43
- CinCor Site 60
- CinCor Site 48
- CinCor Site 32
- CinCor Site 68
- CinCor Site 61
- CinCor Site 55
- CinCor Site 3
- CinCor Site 58
- CinCor Site 62
- CinCor Site 26
- CinCor Site 53
- CinCor Site 10
- CinCor Site 45
- CinCor Site 2
- CinCor Site 5
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
CIN-107 0.5 mg
CIN-107 1 mg
CIN-107 2 mg
Placebo
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks